The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Lycia Therapeutics, a developer of protein-degrading drugs, set terms for an offering that could net the company up to about $265 million.

    Updated Oct. 20, 2026
  • People walking
    Image attribution tooltip

    Commercial stock photo. Standard royalty-free license. Photographer: Simon Kadula

    Image attribution tooltip
    Sponsored by Thermo Fisher Scientific

    How early should you engage a CDMO?

    Discover which CMC activities can move forward early, and which decisions need to remain flexible.

  • Exterior building picture of the Merck KGaA Life Science site in Burlington, U.S.
    Image attribution tooltip
    Courtesy of Merck KGaA
    Image attribution tooltip

    Merck KGaA bets on RNAi with $1.3B Silence buyout

    The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

  • Researcher reviews DNA sequencing data on computer screens.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Hype vs. reality: What pharma’s hottest R&D bets have actually proved

    New types of bispecifics, antibody-drug conjugates and cell therapies haven’t yet proven themselves in the clinic. Pharmaceutical companies are betting billions anyway.

  • A picture of two Iambic Therapeutics executives smiling in front of the Nasdaq logo
    Image attribution tooltip
    Permission granted by 2026 Nasdaq, Inc. / Vanja Savic
    Image attribution tooltip
    Q&A // IPO window

    Iambic CEO on taking an AI drug company public

    Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.

  • A financial graph on an abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Disc’s once-spurned rare disease drug to get a second chance at approval

    Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study

    Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold a second review voucher.

  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: Moderna’s massive stock run

    The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    The 130% premium in Merck KGaA’s buyout of Silence Therapeutics is the second-highest paid in a biopharmaceutical company purchase this year, according to BioPharma Dive data.

    Updated Oct. 19, 2026
  • A magnifying glass enlarges the U.S. Food and Drug Administration website on a computer screen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    FDA ‘reset’ continues with new plan for reviewing rare disease drugs

    A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.

    FDA
  • Front view of the NASDAQ MarketSite, which occupies the northwest corner at the base of the 4 Times Square building, in Midtown Manhattan, New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Next-gen RNAi drugmaker City prices $200M IPO

    The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver. 

  • Rendered illustration of human DNA
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biogen-backed Estuary nabs $93M for kidney disease gene therapy

    The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."

  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Belgian startup revives Galapagos CAR-T research

    Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.

  • An illustration of a pill over an abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Iambic, an AI drug discovery specialist, banks $150M in an IPO

    Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.”

  • Brain alzheimer's
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit

    In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    OMass Therapeutics’ $310 million Series C round is one of the year’s largest private financings involving the venture firms BioPharma Dive tracks.

    Updated Oct. 15, 2026
  • A photo of Wall Street in New York City in 2022.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Another Paragon spinout goes public through reverse merger

    One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform the reputation for reverse mergers — quickly executing on a complicated deal.

  • Pancreatic cancer cells are stained pink in this micrograph image.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Verastem cancer drug shows early promise in small study

    Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.

  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Roche extends China deal streak with $1B pact for RNAi obesity drug

    An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.

  • Banners marking the 2025 American Society of Clinical Oncology's annual meeting hang from the ceiling of a conference hall.
    Image attribution tooltip
    Ned Pagliarulo/BioPharma Dive
    Image attribution tooltip

    The top biopharma conferences in 2027

    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.

  • CVS
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    CVS to pay $315M to settle opioid prescribing allegations

    Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s claims.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    J&J earnings set ‘negative tone’; Shkreli vs. the FTC

    A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.

  • A 3D illustration of a pair of lungs inside the rib cage.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Bristol Myers dips on ‘confounding’ lung drug results

    Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Including its latest deal with Rona Therapeutics, Roche has now inked 10 licensing pacts with China-based drugmakers since the start of 2025. Five have come since late August.

    Updated Oct. 13, 2026
  • A BioNTech logo hangs on the side of an office building.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    BioNTech mRNA cancer immunotherapy misses first objective in key study

    An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is holding out hope it might eventually extend survival.

  • Illustration of a large blue ocean wave cresting against a pale blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pharma’s $500B patent problem will come in waves — not as a cliff

    Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.